Intellia Therapeutics

Derek Hicks, Chief Business Officer

Oct. 11 | 11:15am | UBC Ballroom  

Cambridge, MA 

(NASDAQ: NTLA) 

In-person Presentation 

Intellia Therapeutics is a leading clinical-stage genome editing company, focused on developing novel, potentially curative therapeutics using CRISPR/Cas9 technology. We are building a full-spectrum genome editing company, by leveraging our modular platform, to advance in vivo and ex vivo therapies for diseases with high unmet need. For our in vivo programs to address genetic diseases, we use intravenously administered CRISPR as the therapy, in which our proprietary delivery technology enables highly precise editing of disease-causing genes directly within specific target tissues. For our ex vivo programs to address immuno-oncology and autoimmune diseases, we use CRISPR to create the therapy by engineering cells outside of the body. Our deep scientific, technical, and clinical development experience, along with our robust intellectual property portfolio, enables us to unlock broad therapeutic applications of CRISPR/Cas9 and related technologies to create new classes of genetic medicine. 

www.intelliatx.com



By using this website you agree to accept our Privacy Policy and Terms & Conditions